The three-year signature initiative is designed to make learning about health and disease engaging, accessible, and exciting for students in grades 6-8, primarily in under-resourced schools across the country.
The programme will kick off with a Virtual Field Trip to AstraZeneca's Gaithersburg, MD, research laboratories, which will premiere on Tuesday, October 8, 2019 at 1:00 p.m. ET / 10:00 a.m. PT.
The programme, Generation Health: How Science Powers Us, will provide students first-hand access to the technology and scientists working to create medical breakthroughs for the world's most pressing health problems. Educators, parents and students are invited to register here.
Participants are encouraged to join a live Twitter chat during the premiere by submitting questions and sending pictures using #GenerationHealthVFT.
Generation Health: How Science Powers Us will provide hands-on, standards-aligned STEM learning activities where students investigate both preventative measures and innovative solutions to key health concerns in the areas of oncology, cardiovascular, and respiratory disease.
The programme will also offer resources for employee engagement in the classroom.
As part of this program, Generation Health provides a suite of educational resources, including, Learning Undefeated's Drop Anywhere Labs, custom-outfitted STEM learning spaces built from modified shipping containers.
These light, easy-to-access and inexpensive labs provide a range of career and skills education for middle school students, as well as flexible in-classroom resources that empower teachers and enables them to serve up to four classes simultaneously.
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS